Evidence map›Paper›PMID 36676804›Full record

Observational studyMedicina (Kaunas, Lithuania)2023

A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry.

Sabrina Kepka, Elena-Mihaela Cordeanu, Kevin Zarca, Anne-Sophie Frantz, Patrick Ohlmann, Emmanuel Andres, Pascal Bilbault, Isabelle Durand-Zaleski, Dominique Stephan

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Management of patients hospitalized for SARS-CoV-2 infection: A real-world economic evaluation from the hospital perspective.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Sabrina KepkaEmergency Department, Strasbourg Regional University Hospital, 1 Place de l'Hôpital, 67091 Strasbourg, France.
Elena-Mihaela CordeanuDepartment of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, 67091 Strasbourg, France.
Kevin ZarcaURCEco, Hôtel Dieu, AP-HP, 1 Place du Parvis Notre Dame, 75004 Paris, France.
Anne-Sophie FrantzDepartment of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, 67091 Strasbourg, France.
Patrick OhlmannCardiology Department, Strasbourg Regional University Hospital, 67091 Strasbourg, France.ORCID 0000-0002-8021-2737
Emmanuel AndresInternal Medicine Department, Strasbourg Regional University Hospital, 67091 Strasbourg, France.ORCID 0000-0002-7914-7616
Pascal BilbaultEmergency Department, Strasbourg Regional University Hospital, 1 Place de l'Hôpital, 67091 Strasbourg, France.ORCID 0000-0003-0904-4600
Isabelle Durand-ZaleskiICube, UMR 7357, CNRS, 300 Bd Sébastien Brant, 67400 Illkirch-Graffenstaden, France.ORCID 0000-0002-4078-1476
Dominique StephanDepartment of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, 67091 Strasbourg, France.
Université de Strasbourg · FRCentre National de la Recherche Scientifique · FRInserm · FRAssistance Publique – Hôpitaux de Paris · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

RivaroxabanVenous ThromboembolismAgedAged, 80 and overAnticoagulantsCost-Effectiveness AnalysisFemaleFibrinolytic AgentsHumansMaleMiddle AgedRegistriesVitamin KAnticoagulantsFibrinolytic AgentsRivaroxabanVitamin Kcost-effectivenessdirect oral anticoagulantpulmonary embolismrivaroxabanvenous thromboembolismvitamin K antagonist

Identifiers

PMID36676804
PMCPMC9867052
OpenAlexW4316467934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.